Adial Pharmaceuticals Stock Forecast, Price & News

Adial Pharmaceuticals (NASDAQ:ADIL) Frequently Asked Questions

Is Adial Pharmaceuticals a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adial Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Adial Pharmaceuticals stock.
View analyst ratings for Adial Pharmaceuticals or view top-rated stocks.

How has Adial Pharmaceuticals' stock been impacted by COVID-19?

Adial Pharmaceuticals' stock was trading at $1.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ADIL stock has increased by 73.3% and is now trading at $2.34.
View which stocks have been most impacted by COVID-19.

When is Adial Pharmaceuticals' next earnings date?

Adial Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 28th 2022.
View our earnings forecast for Adial Pharmaceuticals.

How were Adial Pharmaceuticals' earnings last quarter?

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced its quarterly earnings results on Monday, November, 15th. The company reported ($0.22) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.22).
View Adial Pharmaceuticals' earnings history.

What price target have analysts set for ADIL?

4 equities research analysts have issued twelve-month price targets for Adial Pharmaceuticals' shares. Their forecasts range from $5.00 to $15.00. On average, they expect Adial Pharmaceuticals' share price to reach $11.00 in the next year. This suggests a possible upside of 370.1% from the stock's current price.
View analysts' price targets for Adial Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Adial Pharmaceuticals' key executives?

Adial Pharmaceuticals' management team includes the following people:

• William B. Stilley, President, Chief Executive Officer & Director
• Cary J. Claiborne, Chief Operating Officer & Director
• Joseph Truluck, Chief Financial Officer, Secretary & Treasurer
• Bankole A. Johnson, Chief Medical Officer (LinkedIn Profile)
• Julien Dimastromatteo, Vice President-Business Operations & Research

Who are some of Adial Pharmaceuticals' key competitors?

Some companies that are related to Adial Pharmaceuticals include Aptinyx (APTX), Akouos (AKUS), Homology Medicines (FIXX), 9 Meters Biopharma (NMTR), Checkpoint Therapeutics (CKPT), Aldeyra Therapeutics (ALDX), Reneo Pharmaceuticals (RPHM), Athersys (ATHX), Gelesis (GLS), Leap Therapeutics (LPTX), IO Biotech (IOBT), OptiNose (OPTN), Matinas BioPharma (MTNB), Molecular Templates (MTEM) and ZIOPHARM Oncology (ZIOP).
View all of ADIL's competitors.

What other stocks do shareholders of Adial Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adial Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Global Partners (GLP), Corbus Pharmaceuticals (CRBP), Aytu Biopharma (AYTU), T2 Biosystems (TTOO), AIM ImmunoTech (AIM), Tandem Diabetes Care (TNDM), vTv Therapeutics (VTVT), Acasti Pharma (ACST) and Adamis Pharmaceuticals (ADMP).

When did Adial Pharmaceuticals IPO?

(ADIL) raised $8 million in an initial public offering on Friday, July 27th 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Joseph Gunnar & Co. acted as the underwriter for the IPO and Dawson James Securities was co-manager.

What is Adial Pharmaceuticals' stock symbol?

Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL."

How do I buy shares of Adial Pharmaceuticals?

Shares of ADIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adial Pharmaceuticals' stock price today?

One share of ADIL stock can currently be purchased for approximately $2.34.

How much money does Adial Pharmaceuticals make?

Adial Pharmaceuticals has a market capitalization of $48.59 million. The company earns $-10.89 million in net income (profit) each year or ($1.01) on an earnings per share basis.

How many employees does Adial Pharmaceuticals have?

Adial Pharmaceuticals employs 2,018 workers across the globe.

What is Adial Pharmaceuticals' official website?

The official website for Adial Pharmaceuticals is www.adialpharma.com.

Where are Adial Pharmaceuticals' headquarters?

Adial Pharmaceuticals is headquartered at 1180 Seminole Trail Suite 495, Charlottesville VA, 22901.

How can I contact Adial Pharmaceuticals?

Adial Pharmaceuticals' mailing address is 1180 Seminole Trail Suite 495, Charlottesville VA, 22901. The company can be reached via phone at (434) 422-9800 or via email at [email protected].